Acute Bacterial Skin And Skin Structure Infections
(ABSSSI) Treatment Market
Acute Bacterial Skin And Skin Structure Infections
(ABSSSI) Treatment Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size and Growth
The Acute Bacterial Skin and Skin Structure Infections (ABSSSI) treatment market is experiencing significant growth due to rising infection rates and antibiotic resistance. The market size is projected to reach approximately USD 4 billion by 2025, driven by advancements in therapeutics and the increasing prevalence of comorbid conditions escalating ABSSSI incidences.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Furiex Pharmaceuticals, Inc.
◍ GlaxoSmithKline plc
◍ Melinta Therapeutics, Inc.
◍ Debiopharm International S.A.
◍ MerLion Pharmaceuticals Pte Ltd.
◍ Durata Therapeutics, Inc.
◍ Paratek Pharmaceuticals, Inc.
◍ Cempra, Inc.
◍ Abbott Laboratories, Inc.
◍ Actelion Pharmaceuticals Ltd.
◍ Albany Molecular Research, Inc.
◍ Allergan plc.
◍ AstraZeneca
◍ Bayer AG
◍ Macrolide Pharmaceuticals, Inc.
◍ Merck & Co, Inc.
◍ Pfizer, Inc.
The ABSSSI treatment market features major players like GlaxoSmithKline, Merck, and Pfizer, focusing on antibiotic development and innovative therapies. Companies such as Melinta and Durata enhance market growth through novel drug approvals and partnerships.
Sales revenues highlight success, with Pfizer reporting $41.9 billion and Merck at $48 billion annually.
◍ Sanofi
Request Sample Report
Market Segmentation
By Application By Product
Cellulitis
Abscess
Surgical Wounds
Traumatic Wound
Request Sample Report
Delafloxacin
Vancomycin
Ceftaroline Fosamil
Others
Market Growth
Request Sample Report
$ X Billion USD
